004720.Ks
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.04, indicating a conservative leverage position relative to its equity base. With total equity of KRW 146.3 billion and total liabilities of KRW 49.1 billion, the firm maintains a strong balance sheet. The current ratio of 2.85 suggests the company has sufficient short-term assets to cover its short-term liabilities. However, the free cash flow of -KRW 114.8 billion indicates a significant outflow of cash, which may be due to high capital expenditures or operational inefficiencies.
Profitability metrics show a challenging performance, with a return on equity of -79.74% and a return on assets of -59.7%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -KRW 127.3 billion, and the net income is also negative at -KRW 116.7 billion, reflecting a significant loss for the period. These results are below the industry median for profitability metrics, suggesting the company is underperforming relative to its peers.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification may expose the company to higher risks if market conditions in its primary market deteriorate. The absence of detailed segment or geographic breakdown in the provided data limits the ability to assess the extent of revenue concentration.
The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The negative net income and operating income suggest a decline in performance, which may impact future growth prospects. The capital expenditure of -KRW 2.67 billion indicates some investment in long-term assets, but the overall financial performance suggests that the company may need to reassess its growth strategies.
Risk factors include a low liquidity risk, as the company has sufficient cash and equivalents of KRW 21.9 billion to cover short-term obligations. However, the negative free cash flow and high operating losses may pose challenges in maintaining liquidity in the long term. The dilution risk is also low, with no immediate filing-based flags detected. The company's conservative debt structure and strong equity position provide some buffer against dilution pressures.
Recent events, as disclosed in the financial statements, include a significant operating loss and a negative net income. These results may be attributed to increased costs or reduced revenue. The company has not disclosed any major events or strategic initiatives in the provided data, which limits the ability to assess recent developments that may impact its performance.
- The company has a conservative capital structure with a low debt-to-equity ratio of 0.04.
- Profitability is severely underperforming, with a return on equity of -79.74% and a return on assets of -59.7%.
- The company's financial performance is marked by significant operating and net losses, indicating a challenging business environment.
- The company has sufficient liquidity to cover short-term obligations, but the negative free cash flow may impact long-term sustainability.
- There is no immediate dilution risk, but the company's financial performance may require strategic reassessment to ensure long-term growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 004720.KS Market data — financials · 2026-05-26
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → lowlow
- Activity— → Pharmaceuticals & Medical Researchmedium
- Economic sector— → Healthcaremedium